专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US07629369B2 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation 失效
标题翻译： N-苯基芳基磺酰胺化合物，包含该化合物作为活性成分的药物组合物，该化合物的合成中间体及其制备方法
公开(公告)号：US07629369B2
公开(公告)日：2009-12-08
申请号：US11239406
申请日：2005-09-30
申请人： Atsushi Naganawa , Tetsuji Saito , Kaoru Kobayashi , Takayuki Maruyama , Yoshihiko Nakai , Shinsuke Hashimoto
发明人： Atsushi Naganawa , Tetsuji Saito , Kaoru Kobayashi , Takayuki Maruyama , Yoshihiko Nakai , Shinsuke Hashimoto
IPC分类号： C07D285/08 , C07D271/06 , C07D257/04 , A61K31/41
CPC分类号： C07D213/70 , C07D277/36 , C07D307/64 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： An N-phenylarylsulfonylamide compound of formula (I) (R1 is COOH etc.; R2 is hydrogen, methyl, etc.; R3 and R4 are a combination of methyl and methyl, etc.; R5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E2 receptor, especially an EP1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.
摘要翻译：式（I）的N-苯基芳基磺酰胺化合物（R1是COOH等; R2是氢，甲基等; R3和R4是甲基和甲基的组合等; R5是异丙基等; Ar是噻唑基，吡啶基，5-甲基-2-呋喃基，各自任选被甲基取代; n为0或1），化合物的合成中间体及其制备方法。式（I）化合物结合前列腺素E2受体，特别是EP1亚型受体，并拮抗它。蛋白质结合的影响较小，因此具有令人满意的体内活性。因此，认为可用作止痛剂，解热剂，治疗尿频（尿频）和/或下尿路疾病综合征或抗肿瘤药物的药剂。

62. 发明授权

US07601712B2 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient 有权
标题翻译：羧酸化合物和含有与活性成分相同的药物组合物
公开(公告)号：US07601712B2
公开(公告)日：2009-10-13
申请号：US10572578
申请日：2004-09-16
申请人： Atsushi Naganawa , Maki Iwahashi , Atsushi Kinoshita , Atsushi Shimabukuro , Seiji Ogawa , Koji Yano , Kaoru Kobayashi , Yutaka Okada , Yoko Kishida , Shouji Kawauchi , Kohki Tsukamoto , Yoko Matsunaga , Fumio Nambu
发明人： Atsushi Naganawa , Maki Iwahashi , Atsushi Kinoshita , Atsushi Shimabukuro , Seiji Ogawa , Koji Yano , Kaoru Kobayashi , Yutaka Okada , Yoko Kishida , Shouji Kawauchi , Kohki Tsukamoto , Yoko Matsunaga , Fumio Nambu
IPC分类号： A61K31/535 , A61K31/36 , A61K31/34 , A61K31/335 , C07D265/36 , C07D317/44 , C07D307/00 , C07D319/14
CPC分类号： C07D307/80 , A61K31/343 , A61K31/538 , C07D265/36 , C07D317/48
摘要： A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.
摘要翻译：由式（I）表示的化合物，其中式中的符号与说明书中的符号相同，其盐，溶剂合物或其前药与DP受体结合并显示DP受体的拮抗活性。因此，它可用于预防和/或治疗过敏性疾病（例如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），系统性肥大细胞增多症，伴有全身性肥大细胞活化的病症，过敏性休克，支气管收缩，荨麻疹，湿疹，伴有瘙痒的疾病（例如特应性皮炎和荨麻疹），伴随瘙痒的行为的结果产生的疾病（例如白内障，视网膜脱离，炎症，感染和睡眠障碍）（例如，搔抓和殴打），炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿关节炎，胸膜炎，溃疡性结肠炎等。由于其特异性结合DP受体并且弱结合到其他前列腺素受体，它们可以是具有小副作用。

63. 发明授权

US07576129B2 Carboxylic acid compounds 失效
标题翻译：羧酸化合物
公开(公告)号：US07576129B2
公开(公告)日：2009-08-18
申请号：US10544646
申请日：2004-02-06
申请人： Masaki Asada , Kaoru Kobayashi , Masami Narita , Kazutoyo Sato , Atsushi Kinoshita , Toshihiko Nagase , Ken Yoshikawa
发明人： Masaki Asada , Kaoru Kobayashi , Masami Narita , Kazutoyo Sato , Atsushi Kinoshita , Toshihiko Nagase , Ken Yoshikawa
IPC分类号： A61K31/195 , A61K31/34 , C07D317/44 , C07D335/00 , C07C63/00
CPC分类号： C07D213/65 , C07C235/42 , C07C235/44 , C07C235/46 , C07C237/30 , C07D209/18 , C07D209/30 , C07D213/55 , C07D309/14 , C07D317/64 , C07D317/66 , C07D405/12 , C07D407/04 , C07D409/04
摘要： The present invention relates to a carboxylic acid compound of formula (I): wherein R1 is H, alkyl; m is 2, 3; n is 0-2; R2 is phenyl, naphthyl, benzofuran, benzothiophene; Q is —CH2—O-Cyc1, —CH2-Cyc2, -L-Cyc3; R3a and R3b each independently is hydrogen, alkyl or taken together form tetrahydro-2H-pyran; a pharmaceutically acceptable salt thereof, a method for producing a process of the preparation thereof and a pharmaceutical agent comprising the same as an active ingredient. The compound of formula (I) have an antagonizing activity against PGE2 receptor, specifically EP3 receptor which is subtype thereof, and are useful for the prevention and/or treatment of itching, pain, urinary disturbance or stress disease.
摘要翻译：本发明涉及式（I）的羧酸化合物：其中R 1是H，烷基; m为2,3; n为0-2; R2是苯基，萘基，苯并呋喃，苯并噻吩; Q是-CH2-O-Cyc1，-CH2-Cyc2，-L-Cyc3; R3a和R3b各自独立地为氢，烷基或一起形成四氢-2H-吡喃; 其药学上可接受的盐，其制备方法的制备方法和包含其的药剂作为活性成分。式（I）化合物对PGE2受体具有拮抗作用，特别是作为其亚型的EP3受体，可用于预防和/或治疗瘙痒，疼痛，尿失调或应激疾病。

64. 发明申请

US20090180525A1 Signal processing unit and wireless communication device 有权
标题翻译：信号处理单元和无线通信设备
公开(公告)号：US20090180525A1
公开(公告)日：2009-07-16
申请号：US12382157
申请日：2009-03-10
申请人： Kaoru Kobayashi , Shigeru Takegishi
发明人： Kaoru Kobayashi , Shigeru Takegishi
IPC分类号： H04B1/707
CPC分类号： H04B1/70752 , H04L27/0014 , H04L2027/0026 , H04L2027/0051 , H04L2027/0095
摘要： A signal processing unit and a wireless communication device are provided for making it possible to improve detecting sensitivity in correlation peak detecting processing. The signal processing unit and the wireless communication device are comprised of a carrier data generating unit; a carrier demodulation unit; a matched filter unit that carries out despread processing and full addition processing as partial correlation processing for carrier demodulated data, and outputs correlation peak detected data; a correlation peak detecting unit that detects a correlation peak from the correlation detected data and outputs correlation peak position information; a coarse frequency deviation detecting unit that detects a frequency component in accordance with a carrier frequency deviation amount with respect to the carrier demodulated data and outputs a frequency deviation amount to the carrier data generating unit; a fine frequency deviation detecting unit that outputs a fine frequency deviation amount to reduce the frequency deviation amount from the correlation detected data and the correlation peak position information to the carrier data generating unit; and a control unit that inputs the correlation peak position information and adjusts a processing clock signal.
摘要翻译：提供信号处理单元和无线通信设备，用于提高相关峰值检测处理中的检测灵敏度。信号处理单元和无线通信设备包括载波数据生成单元; 载波解调单元; 匹配滤波器单元，其执行解扩处理和全加法处理作为载波解调数据的部分相关处理，并输出相关峰检测数据; 相关峰值检测单元，根据相关检测数据检测相关峰值，并输出相关峰值位置信息; 粗频率偏差检测单元，根据与载波解调数据相关的载波频率偏差量检测频率分量，并向载波数据生成单元输出频率偏差量; 精细频率偏差检测单元，其将相关检测数据和相关峰值位置信息的频率偏差量的精细频率偏差量输出到载波数据生成单元; 以及控制单元，其输入相关峰值位置信息并调整处理时钟信号。

65. 发明申请

US20080197434A1 MAGNETIC MEMORY DEVICE 审中-公开
标题翻译：磁记忆装置
公开(公告)号：US20080197434A1
公开(公告)日：2008-08-21
申请号：US12101607
申请日：2008-04-11
申请人： Yoshihiro Kato , Katsumi Okayama , Kaoru Kobayashi , Tetsuya Yamamoto , Minoru Ikarashi
发明人： Yoshihiro Kato , Katsumi Okayama , Kaoru Kobayashi , Tetsuya Yamamoto , Minoru Ikarashi
IPC分类号： H01L23/552 , H01L29/82
CPC分类号： H01L23/49575 , H01L23/552 , H01L2924/0002 , H01L2924/00
摘要： A magnetic memory device in which an MRAM element is magnetically shielded from large external magnetic fields. The magnetic memory device includes: a substrate; a magnetic random access memory mounted on the substrate, the magnetic random access memory including a memory element having a magnetized pinned layer with fixed direction of magnetization and a magnetic layer with changeable direction of magnetization stacked on one another; another element mounted on the substrate; and a pair of magnetic shielding layers which magnetically shield the memory element, the magnetic shielding layers located relatively above and below the memory element and within a region corresponding to an area occupied by the memory element.
摘要翻译：一种磁存储器件，其中MRAM元件与大的外部磁场磁屏蔽。磁存储器件包括：基片; 安装在基板上的磁性随机存取存储器，所述磁性随机存取存储器包括具有固定磁化方向的磁化钉扎层和具有可变方向磁化的磁性层彼此叠置的存储元件; 安装在基板上的另一元件; 以及一对磁屏蔽层，其对存储元件进行磁屏蔽，磁屏蔽层位于相对于存储元件的上方和下方并且在对应于存储元件所占据的区域的区域内。

66. 发明授权

US07402605B2 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient 失效
标题翻译： 8-氮杂的前列腺素衍生物化合物和含有这些化合物作为活性成分的药物
公开(公告)号：US07402605B2
公开(公告)日：2008-07-22
申请号：US10506536
申请日：2003-03-04
申请人： Kousuke Tani , Kaoru Kobayashi , Toru Maruyama , Tohru Kambe , Mikio Ogawa , Tsutomu Shiroya
发明人： Kousuke Tani , Kaoru Kobayashi , Toru Maruyama , Tohru Kambe , Mikio Ogawa , Tsutomu Shiroya
IPC分类号： A61K31/40 , C07D207/00
CPC分类号： C07D413/06 , C07D207/26 , C07D263/24 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12 , C07D413/12 , C07D417/06 , C07D417/12
摘要： An 8-azaprostaglandin represented by formula (I) (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof. Since the compound represented by formula (I) binds to EP2 subtype among PGE receptor strongly, it is useful for preventive and/or treatment for immune diseases, allergic diseases, neuronal cell death, dysmenorrhea, premature birth, abortion, baldness, retinal neuropathy such as glaucoma, erectile dysfunction, arthritis, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, hepatic injury, acute hepatitis, liver cirrhosis, shock, nephritis, renal failure, circulatory diseases, systemic inflammatory response syndrome, sepsis, hemophagocytosis syndrome, macrophage activation syndrome, still disease, Kawasaki Disease, burn, systemic granuloma, ulcerative colitis, Crohn disease, hypercytokinemia at dialysis, multiple organ failure, or bone diseases etc.
摘要翻译：由式（I）（其中所有符号具有与说明书中所述相同的含义）表示的8-氮杂前列腺素，其药学上可接受的盐或其环糊精包合物。由于式（I）表示的化合物强烈地与PGE受体中的EP2亚型结合，因此可用于免疫疾病，过敏性疾病，神经元细胞死亡，痛经，早产，流产，秃发，视网膜神经病变等的预防和/或治疗青光眼，勃起功能障碍，关节炎，肺损伤，肺纤维化，肺气肿，支气管炎，慢性阻塞性肺病，肝损伤，急性肝炎，肝硬化，休克，肾炎，肾衰竭，循环系统疾病，全身炎症反应综合征，败血症，血细胞增多综合征，巨噬细胞活化综合征，静止病，川崎病，烧伤，全身肉芽肿，溃疡性结肠炎，克罗恩病，透析中的高细胞因子血症，多器官功能衰竭或骨骼疾病等。

67. 发明申请

US20060045543A1 Electromagnetism suppressing material, electromagnetism suppressing device, and electronic appliance 审中-公开
标题翻译：电磁抑制材料，电磁抑制装置和电子设备
公开(公告)号：US20060045543A1
公开(公告)日：2006-03-02
申请号：US11185879
申请日：2005-07-21
申请人： Yoshihiro Kato , Yoshinori Ito , Katsumi Okayama , Kaoru Kobayashi , Masaki Orihashi , Makoto Suzuki , Takashi Miyazaki
发明人： Yoshihiro Kato , Yoshinori Ito , Katsumi Okayama , Kaoru Kobayashi , Masaki Orihashi , Makoto Suzuki , Takashi Miyazaki
IPC分类号： G03G15/00
CPC分类号： H05K9/0075
摘要： An electromagnetism suppressing material has an increased electromagnetism suppressing effect, can be flexibly formed in various shapes, and is inexpensive. An electromagnetism suppressing device uses the electromagnetism suppressing material, and an electronic appliance uses the electromagnetism suppressing material or the electromagnetism suppressing device. The electromagnetism suppressing material is a liquid material and/or gel material with electrical polarity.
摘要翻译：电磁抑制材料具有增加的电磁抑制效果，可以灵活地形成各种形状，并且便宜。电磁抑制装置使用电磁抑制材料，电子设备使用电磁抑制材料或电磁抑制装置。电磁抑制材料是具有电极性的液体材料和/或凝胶材料。

68. 发明授权

US06992155B2 Method for producing magnetic particle, magnetic particle and magnetic material 有权
标题翻译：磁粉，磁粉和磁性材料的制造方法
公开(公告)号：US06992155B2
公开(公告)日：2006-01-31
申请号：US10245046
申请日：2002-09-17
申请人： Katsumi Okayama , Kaoru Kobayashi , Koichiro Inomata , Satoshi Sugimoto , Yoshihiro Kato
发明人： Katsumi Okayama , Kaoru Kobayashi , Koichiro Inomata , Satoshi Sugimoto , Yoshihiro Kato
IPC分类号： C08F4/42 , C08K3/10 , C08K3/18 , B32B15/02 , B32B15/08
CPC分类号： B82Y30/00 , B22F1/0018 , B22F1/0059 , B22F9/24 , B22F9/305 , B22F2998/00 , B82Y25/00 , B82Y40/00 , C22C32/0094 , H01F1/0054 , H01F41/30 , H01F41/301 , Y10S977/777 , Y10S977/783 , Y10T428/12146 , Y10T428/254 , Y10T428/256 , Y10T428/257 , Y10T428/29 , Y10T428/2991 , Y10T428/2998 , B22F3/02
摘要： A method for producing a magnetic particle forming a magnetic material for absorbing electromagnetic waves comprises the steps of mixing an organometallic complex or a metal salt with a chain polymer and dissolving the mixture in a solvent (step S1); raising the temperature of the mixture to reaction temperature (step S2), carrying out a reaction at the reaction temperature (step S3); and forming the magnetic particle having a structure that the periphery of each fine particle formed from the organometallic complex or the metal salt is surrounded by the chain polymer and recovering the formed magnetic particle after the reaction (step S4). The magnetic particle has a nanogranular structure to become a magnetic material for absorbing electromagnetic waves. Such a magnetic particle is produced by a wet reaction. Thus, a larger amount of magnetic particle can be produced by one reaction.
摘要翻译：形成用于吸收电磁波的磁性材料的磁性颗粒的制造方法包括将有机金属络合物或金属盐与链状聚合物混合并将该混合物溶解在溶剂中的步骤（步骤S1）。将混合物的温度升至反应温度（步骤S2），在反应温度下进行反应（步骤S3）; 并形成具有由有机金属配合物或金属盐形成的各微细颗粒的周围被链状聚合物包围并在反应后回收形成的磁性颗粒的结构的磁性颗粒（步骤S4）。磁性颗粒具有纳米结构，成为吸收电磁波的磁性材料。这样的磁性颗粒是通过湿反应产生的。因此，通过一次反应可以产生更大量的磁性颗粒。

69. 发明申请

US20050124672A1 N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same 有权
标题翻译：含有化合物作为化合物的活性成分中间体的N-苯基芳基磺酰胺化合物药物及其制备方法
公开(公告)号：US20050124672A1
公开(公告)日：2005-06-09
申请号：US10471673
申请日：2002-03-11
申请人： Atsushi Naganawa , Tetsuji Saito , Kaoru Kobayashi , Takayuki Maruyama , Yoshihiko Nakai , Shinsuke Hashimoto
发明人： Atsushi Naganawa , Tetsuji Saito , Kaoru Kobayashi , Takayuki Maruyama , Yoshihiko Nakai , Shinsuke Hashimoto
IPC分类号： C07D307/64 , A61K31/34 , A61K31/341 , A61K31/41 , A61K31/4245 , A61K31/426 , A61K31/427 , A61K31/4402 , A61K31/4406 , A61K31/4439 , A61P1/04 , A61P13/00 , A61P13/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D213/70 , C07D213/71 , C07D277/20 , C07D277/36 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12
CPC分类号： C07D213/70 , C07D277/36 , C07D307/64 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： An N-phenylarylsulfonylamide compound of formula (I) (R1 is COOH etc.; R2 is hydrogen, methyl, etc.; R3 and R4 are a combination of methyl and methyl, etc.; R5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E2 receptor, especially an EP1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.
摘要翻译：式（I）的N-苯基芳基磺酰胺化合物（R 1）是COOH等; R 2是氢，甲基等; R 3 O >和R 4是甲基和甲基等的组合; R 5是异丙基等; Ar是噻唑基，吡啶基，5-甲基-2-呋喃基任选被甲基取代; n为0或1），化合物的合成中间体及其制备方法。式（I）化合物与前列腺素E 2受体结合，特别是EP 1亚型受体，并拮抗它。蛋白质结合的影响较小，因此具有令人满意的体内活性。因此，认为可用作止痛剂，解热剂，治疗尿频（尿频）和/或下尿路疾病综合征或抗肿瘤药物的药剂。

70. 发明申请

US20050004097A1 Indole derivatives 失效
标题翻译：吲哚衍生物
公开(公告)号：US20050004097A1
公开(公告)日：2005-01-06
申请号：US10488835
申请日：2002-09-06
申请人： Kazuhiko Torisu , Maki Iwahashi , Kaoru Kobayashi , Fumio Nambu
发明人： Kazuhiko Torisu , Maki Iwahashi , Kaoru Kobayashi , Fumio Nambu
IPC分类号： A61K31/404 , A61K31/405 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/423 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/497 , A61K31/498 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5415 , C07D209/08 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D411/12 , C07D413/12 , C07D417/12 , C07D498/04 , C07
CPC分类号： A61K31/405 , A61K31/404 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/423 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/497 , A61K31/498 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5415 , C07D209/08 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D411/12 , C07D413/12 , C07D417/12
摘要： Compounds represented by formula (I) wherein all symbols represent the same meanings as described in specification. and salts thereof. Since the compound represented by the formula (I) binds and antagonizes to DP receptor, it is useful for the prevention or treatment against the disease such as allergic disorder, diseases accompanied with itching, secondary diseases generated by behaviors caused by itching, inflammation, chronic obstructive pulmonary disease, ischemic reperfusion disorder, pleuritis complicated by rheumatoid arthritis, cerebrovascular disease, and ulcerative colitis.
摘要翻译：由式（I）表示的化合物，其中所有符号表示与说明书中所述相同的含义。及其盐。由于式（I）表示的化合物与DP受体结合并拮抗，因此可用于预防或治疗诸如过敏性疾病，伴有瘙痒的疾病，由瘙痒引起的行为引起的继发性疾病，炎症，慢性阻塞性肺病，局部缺血再灌注障碍，类风湿关节炎并发的胸膜炎，脑血管疾病和溃疡性结肠炎。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式